AbbVie News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

07.10.21	AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis (PR Newswire)
07.10.21	AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis (PR Newswire)
05.10.21	AbbVie to Host Third-Quarter 2021 Earnings Conference Call (PR Newswire)
03.10.21	AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021 (PR Newswire)
30.09.21	AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress (PR Newswire)
30.09.21	AbbVie: New Analysis Show RINVOQ's Potential To Alleviate Itch And Rash In Atopic Dermatitis (RTTNews)
30.09.21	AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress (PR Newswire)
29.09.21	FDA Approves AbbVie's Qulipta For Preventive Treatment Of Migraine (RTTNews)
29.09.21	FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine (PR Newswire)
27.09.21	Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals (PR Newswire)
23.09.21	AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress (PR Newswire)
20.09.21	AbbVie Seeks Approval For SKYRIZI Based On Data From Three Phase 3 Studies (RTTNews)
20.09.21	AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease (PR Newswire)
16.09.21	AbbVie Files For FDA And EMA Approval Of Upadacitinib For Ulcerative Colitis (RTTNews)
16.09.21	AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (PR Newswire)
13.09.21	AbbVie Inks Eye Care Deal With REGENXBIO (RTTNews)
13.09.21	AbbVie and REGENXBIO Announce Eye Care Collaboration (PR Newswire)
10.09.21	AbbVie Declares Quarterly Dividend (PR Newswire)
10.09.21	AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021 (PR Newswire)
09.09.21	Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet (PR Newswire)
08.09.21	AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress (PR Newswire)
30.08.21	Biotech Stocks Facing FDA Decision In September 2021 (RTTNews)
24.08.21	AbbVie Announces EC Approval Of RINVOQ In Treatment Of Moderate To Severe Atopic Dermatitis (RTTNews)
24.08.21	European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis (PR Newswire)
18.08.21	New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine (PR Newswire)
09.08.21	AbbVie Launches SKYRIZI As Single-dose 150 Mg Injection - Quick Facts (RTTNews)
09.08.21	SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis (PR Newswire)
04.08.21	JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Ad... (PR Newswire)
03.08.21	Abbott's Subsidiaries Agree To Pay $160 Mln To Settle Alleged False Claims To Medicare (RTTNews)
30.07.21	AbbVie Lifts FY Adj. Profit View (RTTNews)
30.07.21	AbbVie Q2 adjusted earnings Beat Estimates (RTTNews)
30.07.21	AbbVie Reports Second-Quarter 2021 Financial Results (PR Newswire)
29.07.21	AbbVie : FDA Oks Expanded BOTOX Label To Include Eight New Muscles To Treat Upper Limb Spasticity (RTTNews)
29.07.21	FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity (PR Newswire)
27.07.21	AbbVie, Calico Again Extend Collaboration Focused On Aging And Age-Related Diseases (RTTNews)
27.07.21	AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases (PR Newswire)
25.07.21	New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition (PR Newswire)
24.07.21	FDA Approves AbbVie's Dalvance To Treat Acute Bacterial Skin & Skin Structure Infections In Children (RTTNews)
23.07.21	DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients (PR Newswire)
21.07.21	AbbVie: Venetoclax Gets FDA's Breakthrough Therapy Designation In Higher Risk MDS (RTTNews)
21.07.21	Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS) (PR Newswire)
20.07.21	Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting (PR Newswire)
16.07.21	Lilly : FDA Delays Review Of Baricitinib SNDA On Atopic Dermatitis (RTTNews)
16.07.21	AbbVie : FDA Didn't Meet PDUFA Action Date For SNDA Of RINVOQ On Atopic Dermatitis Treatment (RTTNews)
16.07.21	AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S. (PR Newswire)
07.07.21	AbbVie to Host Second-Quarter 2021 Earnings Conference Call (PR Newswire)
29.06.21	AbbVie Says Phase 3 Ulcerative Colitis Maintenance Study Met Primary Endpoint - Quick Facts (RTTNews)
29.06.21	Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients (PR Newswire)
28.06.21	AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO) (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester